Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Janet Alvarado

Internal Medicine Highland, IL Medical Doctor

NPI 1336114818 CMS profile 242092

821 Poplar Street, Highland, IL 62249

Open in the dashboard

General payments

$4,630

201 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Janet Alvarado of Highland, IL is reported in the CMS Open Payments database as having received $4,630 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $112 3
2022 General $1,473 57
2021 General $589 25
2020 General $298 18
2019 General $2,158 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janet Alvarado
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Janet Alvarado were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Janet Alvarado Internal Medicine median Middle half National median
2019 $2,158 $159 $48–$570 $163
2020 $298 $119 $33–$402 $114
2021 $589 $135 $37–$521 $132
2022 $1,473 $141 $42–$496 $149
2023 $112 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Organogenesis Inc. $973 24 payments
  2. AstraZeneca Pharmaceuticals LP $725 19 payments
  3. AbbVie, Inc. $491 24 payments
  4. Acera Surgical, Inc. $415 31 payments
  5. Novo Nordisk Inc $376 18 payments
  6. Lilly USA, LLC $315 14 payments
  7. Janssen Pharmaceuticals, Inc $246 8 payments
  8. Amarin Pharma Inc. $189 8 payments
  9. Allergan Inc. $166 7 payments
  10. Astellas Pharma US Inc $99 5 payments
  11. Other $634 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,593 197 payments
  2. Education $21 3 payments
  3. Debt forgiveness $15 1 payment
Products named General payments · program years 2019–2023
  1. Restrata Wound Matrix $402 30 payments
  2. UBRELVY $358 13 payments
  3. Puraply $356 9 payments
  4. Ozempic $280 11 payments
  5. FARXIGA $275 11 payments
  6. Apligraf $231 5 payments
  7. BREZTRI $218 4 payments
  8. Puraply, NuShield, Affinity $202 5 payments
  9. TRULICITY $198 11 payments
  10. Vascepa $159 6 payments
  11. Other $2,706 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Internal Medicine: 777

Drug cost

$202

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 13 $202

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$3,590

Medicare's payments for the services billed

Medicare patients

40

Average age 73

Services billed

83

21 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Heart failure 63%
Ischemic heart disease 58%
Diabetes 53%
Chronic kidney disease 50%
COPD 50%
Atrial fibrillation 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record